Monday, April 18, 2016

Rituximab shows second-line promise in autoimmune limbic encephalitis

Rituximab shows second-line promise in autoimmune limbic encephalitis: Rituximab is an effective and well-tolerated second-line treatment for patients with autoimmune limbic encephalitis, suggests research.

No comments:

Post a Comment